| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Total revenues | $3.4M-67.7% | $10.5M-77.5% | $46.7M+32.2% | $35.3M+323.2% | $8.3M-89.1% | $76.4M | $0-100.0% | $10.7M+293.9% | $2.7M |
| Cost of revenue | $26K-96.9% | $845K-69.4% | $2.8M-98.1% | $146.3M+122.1% | $65.9M | $0 | $0 | — | — |
| Research and development | $456.0M-10.0% | $506.5M-12.6% | $579.7M+22.1% | $474.6M+5.9% | $448.0M+48.1% | $302.4M+103.7% | $148.5M+48.1% | $100.2M+60.3% | $62.5M |
| Selling, general and administrative | $92.1M-22.6% | $119.0M-31.8% | $174.4M+7.8% | $161.8M+0.6% | $160.8M+126.7% | $70.9M+88.7% | $37.6M | — | — |
| Restructuring, long-lived assets impairment and related charges, net | -$182K-100.5% | $35.0M+158.1% | $13.6M | $0 | — | — | — | — | — |
| Total operating expenses | $547.9M-17.2% | $661.4M-14.2% | $770.5M-1.6% | $782.7M+16.0% | $674.7M+80.7% | $373.3M+100.6% | $186.1M+43.8% | $129.4M+53.6% | $84.2M |
| Loss from operations | -$479.3M+18.4% | -$587.2M+14.2% | -$684.3M-182.1% | $833.1M+98.0% | $420.8M+241.7% | -$297.0M-66.9% | -$178.0M-50.0% | -$118.7M-45.6% | -$81.5M |
| Change in fair value of equity investments | $1.7M+131.3% | -$5.5M+74.7% | -$21.9M+80.3% | -$111.1M-180.5% | $138.0M | $0 | $0 | — | — |
| Interest income | $40.2M-44.0% | $71.8M-17.5% | $87.0M+209.7% | $28.1M+6299.1% | $439K-84.5% | $2.8M-66.7% | $8.5M+235.1% | $2.5M+298.1% | $638K |
| Other expense, net | -$409K+81.6% | -$2.2M+75.3% | -$9.0M-311.1% | $4.3M+145.1% | -$9.4M-111.3% | -$4.5M+11.7% | -$5.1M-2287.3% | -$212K-355.4% | $83K |
| Total other income | $41.6M-35.1% | $64.1M+14.2% | $56.1M+171.2% | -$78.8M-161.1% | $129.1M+8012.4% | -$1.6M+52.7% | -$3.5M-248.2% | $2.3M+222.9% | $721K |
| Loss before (provision for) benefit from income taxes | -$437.8M+16.3% | -$523.1M+16.7% | -$628.2M-183.3% | $754.3M+37.2% | $549.8M+284.1% | -$298.6M-71.1% | -$174.5M-50.0% | -$116.4M-44.1% | -$80.8M |
| (Provision for) benefit from income taxes | -$217K-119.0% | $1.1M-91.2% | $13.1M+105.5% | -$238.4M-1023.8% | -$21.2M-39192.6% | -$54K+64.9% | -$154K-132.1% | $480K-95.6% | $10.9M |
| Net loss | -$438.0M+16.1% | -$522.0M+15.1% | -$615.1M-219.2% | $515.8M | — | — | — | -$115.9M-65.9% | -$69.9M |
| Net loss attributable to noncontrolling interest | $0 | $0+100.0% | -$56K | $0 | $0 | — | — | — | — |
| Net loss attributable to Vir Bio | -$438.0M+16.1% | -$522.0M+15.1% | -$615.1M-219.2% | $515.8M-2.4% | $528.6M+277.0% | -$298.7M-71.0% | -$174.7M-50.7% | -$115.9M-65.9% | -$69.9M |
| Net loss per share attributable to VirBio, basic (in USD per share) | -$3160.00+17.5% | -$3830.00+16.6% | -$4590.00-218.0% | $3890.00+95477.4% | $4.07+100.2% | -$2510.00+56.4% | -$5760.00 | — | — |
| Net loss per share attributable to VirBio, diluted (in USD per share) | -$3160.00+17.5% | -$3830.00+16.6% | -$4590.00-219.8% | $3830.00+96617.2% | $3.96+100.2% | -$2510.00+56.4% | -$5760.00 | — | — |
| Weighted-average shares outstanding, basic (in shares) | 138.52B+1.7% | 136.25B+1.6% | 134.13B+1.1% | 132.61B+101995.5% | 129.9M-99.9% | 119.16B+292.6% | 30.35B | — | — |
| Weighted-average shares outstanding, diluted (in shares) | 138.52B+1.7% | 136.25B+1.6% | 134.13B-0.5% | 134.81B+100929.5% | 133.4M-99.9% | 119.16B+292.6% | 30.35B | — | — |
| License and collaboration revenue | |||||||||
| Grant revenue | |||||||||
| Other revenue | |||||||||
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Source: SEC EDGAR 10-K and 10-Q filings. Up to 10 years annual / 16 quarters shown.